Cardiology – Medxy AI

Challenging the Label: Large-Scale Meta-Analysis Refutes Most Statin-Attributed Adverse Effects

By MedXY 02/16/2026

A comprehensive meta-analysis of double-blind RCTs by the CTT Collaboration reveals that the majority of adverse effects listed on statin labels, including cognitive and sleep issues, lack causal evidence, suggesting a need for urgent regulatory revisions.

Cardiology news Pediatrics

Early Life Origins of Hypertension: Longitudinal Evidence That Blood Pressure Tracks from Birth to School Age

By MedXY 02/10/2026

A longitudinal study of the ENVIRONAGE cohort reveals that blood pressure tracks consistently from birth through childhood, with higher neonatal readings significantly increasing the risk of hypertension by age 11, emphasizing the need for early life cardiovascular monitoring.

Cardiology Emergency Medicine news

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks

By MedXY 02/08/2026

An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Cardiology Diabetes & Endocrinology news

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

By MedXY 02/04/2026

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible tool for identifying high-risk patients.

Cardiology Infectious Diseases news

The Multi-Billion Dollar Toll of Chagas Disease: Why Aging Populations and Chronic Cardiac Care are Driving Economic Burden in Latin America

By MedXY 01/30/2026

A comprehensive cost-of-illness analysis from the RAISE study reveals that Chagas disease imposes a massive economic burden on Latin American countries, driven by a shift toward chronic cardiac complications in aging populations, despite declining overall prevalence.

Cardiology news Psychiatry

PTSD and Sleep Disorders Linked to Sharp Rise in Acute Coronary Syndrome Risk

By MedXY 01/27/2026

A comprehensive meta-analysis of over 22 million individuals identifies mental disorders, particularly PTSD and sleep disturbances, as major independent risk factors for acute coronary syndrome, urging a paradigm shift toward integrated cardiovascular and psychiatric care.

AI Cardiology news

AI-ECG Models for Heart Failure Screening Show High Accuracy in First-of-its-Kind Independent Comparison Study

By MedXY 01/26/2026

This independent validation study confirms that AI-enhanced ECG models effectively detect left ventricular systolic dysfunction across diverse populations, achieving AUROCs up to 0.93. However, significant barriers remain regarding model transparency and data sharing for clinical implementation.

Cardiology Diabetes & Endocrinology news

Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia

By MedXY 01/25/2026

Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where traditional therapies often fail.

Cardiology Internal Medicine news Pathology & Lab Medicine

NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?

By MedXY 01/18/2026

A post hoc analysis of the ASPREE trial reveals that heart stress, measured by NT-proBNP, significantly alters the relationship between blood pressure and cardiovascular risk in older adults, suggesting a paradigm shift toward biomarker-guided hypertension management.

Cardiology news

DOACs After Left Atrial Appendage Closure: Enhancing Safety Without Compromising Efficacy in the ANDES Trial

By MedXY 01/18/2026

The ANDES randomized trial demonstrates that 60-day DOAC therapy post-LAAC significantly reduces bleeding events compared to DAPT, while maintaining comparable rates of device-related thrombosis, suggesting a superior safety profile for short-term anticoagulation.

Cardiology Critical Care news

Mechanical Thrombectomy Superior to Anticoagulation Alone for Rapid Right Ventricular Recovery in Intermediate-High Risk Pulmonary Embolism: Results from the STORM-PE Trial

By MedXY 01/18/2026

The STORM-PE trial, the first randomized controlled trial of its kind, demonstrates that computer-assisted vacuum thrombectomy (CAVT) significantly improves right ventricular recovery and reduces clot burden compared to anticoagulation alone in patients with intermediate-high risk pulmonary embolism.

Cardiology news

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

By MedXY 01/17/2026

The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with comparable safety profiles between both regimens.

Cardiology Internal Medicine news

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

By MedXY 01/17/2026

The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering ischemic risks without increasing bleeding.

Cardiology news

Vericiguat in Compensated HFrEF: Navigating the Complex Results of the VICTOR Trial and the Burden of Outpatient Worsening

By MedXY 01/17/2026

The VICTOR trial evaluated vericiguat in stable HFrEF outpatients. While the primary endpoint was not met, exploratory analyses revealed significant mortality reductions and highlighted the prognostic importance of outpatient heart failure worsening, suggesting a broader clinical role for sGC stimulators.

Cardiology news

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial

By MedXY 01/16/2026

The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis, potentially redefining the standard of care.

Cardiology Internal Medicine news

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?

By MedXY 01/16/2026

This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest a potential clinical benefit in treatment intensification and family communication.

Cardiology Nephrology news

Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease

By MedXY 01/10/2026

The FIVE-STAR trial reveals that finerenone's cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease.

Cardiology news Psychiatry

The Hidden Burden of Heart and Brain Health: ASCVD Linked to Significantly Elevated Suicide Risk

By MedXY 01/07/2026

A large-scale nationwide study reveals that individuals with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke, face a 43% higher risk of suicide. The risk nearly doubles for those suffering from both conditions, highlighting an urgent need for mental health integration in cardiovascular care.

Cardiology Hematology-Oncology news

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients

By MedXY 01/05/2026

A post hoc analysis of the AVERT trial identifies GDF-15, NT-proBNP, CRP, and hs-TnT as significant predictors for venous thromboembolism and bleeding in cancer patients, offering new tools for personalized risk stratification.